AVAH vs INFU
AVAH: A high-growth home health, hospice, and durable medical equipment provider consolidating a fragmented market while navigating significant Medicare/Medicaid reimbursement headwinds. INFU: InfuSystem is a specialized provider of durable medical equipment and managed healthcare services that enables the seamless transition of oncology and other infusion therapies from clinical settings to the home.
Side-by-side fundamentals
| Metric | AVAH | INFU | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.43 | $8.90 | |
| Market cap as of 2026-07-23 | $2.1B | $185M | |
| P/E as of 2026-07-23 | 7.85 | 23.34 | AVAH lower |
| PEG as of 2026-07-23 | 0.47 | 0.16 | INFU lower |
| Net margin as of 2026-07-23 | +10.4% | +5.6% | AVAH higher |
| Gross margin as of 2026-07-23 | +33.0% | +56.8% | INFU higher |
| Operating margin as of 2026-07-23 | +10.6% | +9.1% | AVAH higher |
| ROE as of 2026-07-23 | +157.8% | +14.0% | AVAH higher |
| ROA as of 2026-07-23 | +13.7% | +7.9% | AVAH higher |
| Debt / equity as of 2026-07-23 | 6.07 | 0.33 | INFU lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.5% | +3.5% | AVAH higher |
| Revenue CAGR (3y) SEC XBRL | +8.0% | +9.3% | INFU higher |
| Beta as of 2026-07-23 | 1.95 | 1.49 | |
| 1-year return as of 2026-07-22 close | +141.7% | +66.1% | AVAH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.